These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24953396)

  • 1. Familial hypercholesterolemia: etiology, diagnosis and new treatment options.
    Gouni-Berthold I; Berthold HK
    Curr Pharm Des; 2014; 20(40):6220-9. PubMed ID: 24953396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
    Patel RS; Scopelliti EM; Savelloni J
    Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Therapeutic Approaches for Familial Hypercholesterolemia.
    Ajufo E; Rader DJ
    Annu Rev Med; 2018 Jan; 69():113-131. PubMed ID: 29414257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial Hypercholesterolemia: Global Burden and Approaches.
    Tokgozoglu L; Kayikcioglu M
    Curr Cardiol Rep; 2021 Sep; 23(10):151. PubMed ID: 34480646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B antisense inhibition--update on mipomersen.
    Gebhard C; Huard G; Kritikou EA; Tardif JC
    Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial Hypercholesterolemia: Advances in Recognition and Therapy.
    Cartier JL; Goldberg AC
    Prog Cardiovasc Dis; 2016; 59(2):125-134. PubMed ID: 27477957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New lipid lowering agents].
    Cuevas A; Farías MM; Alonso R
    Rev Med Chil; 2014 Jul; 142(7):880-8. PubMed ID: 25378007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.